Do analysts rate SCLX or HOWL?

Werewolf Therapeutics has a consensus price target of $3.75, indicating a potential upside of 1,001.65%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14

Is HOWL or CYPH more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% Cypherpunk Technologies N/A -48.33% -42.21%

Is HOWL or ANVS more profitable?

Werewolf Therapeutics' return on equity of -208.23% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% Annovis Bio N/A -318.08% -215.47%

Werewolf Therapeutics (HOWL) Competitors

$0.34 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.33 -0.01 (-2.47%)

As of 07/2/2026 06:11 PM Eastern

Compare

HOWL vs. SCLX, CYPH, MNOV, ANVS, and TCRX

Should you buy Werewolf Therapeutics stock or one of its competitors? MarketBeat compares Werewolf Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Werewolf Therapeutics include Scilex (SCLX), Cypherpunk Technologies (CYPH), MediciNova (MNOV), Annovis Bio (ANVS), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry.

How does Werewolf Therapeutics compare to Scilex?

Scilex (NASDAQ:SCLX) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, Scilex's average media sentiment score of 0.00 equaled Werewolf Therapeutics'average media sentiment score.

Company	Overall Sentiment
Scilex	Neutral
Werewolf Therapeutics	Neutral

Werewolf Therapeutics has a consensus price target of $3.75, indicating a potential upside of 1,001.65%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Werewolf Therapeutics has lower revenue, but higher earnings than Scilex. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	2.19	-$358.73M	-$40.47	N/A
Werewolf Therapeutics	$1.88M	8.80	-$60.82M	-$1.24	N/A

Scilex has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

69.7% of Scilex shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 4.5% of Scilex shares are owned by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Werewolf Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

Summary

Werewolf Therapeutics beats Scilex on 9 of the 14 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Cypherpunk Technologies?

Werewolf Therapeutics (NASDAQ:HOWL) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Werewolf Therapeutics currently has a consensus price target of $3.75, suggesting a potential upside of 1,001.65%. Cypherpunk Technologies has a consensus price target of $0.90, suggesting a potential upside of 35.14%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Werewolf Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cypherpunk Technologies has lower revenue, but higher earnings than Werewolf Therapeutics. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	8.80	-$60.82M	-$1.24	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Cypherpunk Technologies had 2 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 2 mentions for Cypherpunk Technologies and 0 mentions for Werewolf Therapeutics. Cypherpunk Technologies' average media sentiment score of 0.50 beat Werewolf Therapeutics' score of 0.00 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Werewolf Therapeutics	Neutral
Cypherpunk Technologies	Positive

Cypherpunk Technologies' return on equity of -48.33% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

Werewolf Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market.

Summary

Werewolf Therapeutics beats Cypherpunk Technologies on 8 of the 14 factors compared between the two stocks.

How does Werewolf Therapeutics compare to MediciNova?

MediciNova (NASDAQ:MNOV) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

In the previous week, MediciNova had 2 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 2 mentions for MediciNova and 0 mentions for Werewolf Therapeutics. MediciNova's average media sentiment score of 0.00 equaled Werewolf Therapeutics'average media sentiment score.

Company	Overall Sentiment
MediciNova	Neutral
Werewolf Therapeutics	Neutral

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 14.0% of MediciNova shares are owned by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Werewolf Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

MediciNova has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

MediciNova has higher earnings, but lower revenue than Werewolf Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	171.67	-$12M	-$0.23	N/A
Werewolf Therapeutics	$1.88M	8.80	-$60.82M	-$1.24	N/A

MediciNova currently has a consensus price target of $8.33, suggesting a potential upside of 482.75%. Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 1,001.65%. Given Werewolf Therapeutics' higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

MediciNova beats Werewolf Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Annovis Bio?

Werewolf Therapeutics (NASDAQ:HOWL) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Annovis Bio has lower revenue, but higher earnings than Werewolf Therapeutics. Annovis Bio is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	8.80	-$60.82M	-$1.24	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

In the previous week, Annovis Bio had 2 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 2 mentions for Annovis Bio and 0 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score.

Company	Overall Sentiment
Werewolf Therapeutics	Neutral
Annovis Bio	Neutral

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Werewolf Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

Werewolf Therapeutics' return on equity of -208.23% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
Annovis Bio	N/A	-318.08%	-215.47%

Werewolf Therapeutics presently has a consensus price target of $3.75, suggesting a potential upside of 1,001.65%. Annovis Bio has a consensus price target of $13.50, suggesting a potential upside of 597.67%. Given Werewolf Therapeutics' higher possible upside, equities research analysts clearly believe Werewolf Therapeutics is more favorable than Annovis Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Werewolf Therapeutics beats Annovis Bio on 8 of the 12 factors compared between the two stocks.

How does Werewolf Therapeutics compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Werewolf Therapeutics has lower revenue, but higher earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	6.71	-$129.77M	-$0.96	N/A
Werewolf Therapeutics	$1.88M	8.80	-$60.82M	-$1.24	N/A

In the previous week, TScan Therapeutics' average media sentiment score of 0.00 equaled Werewolf Therapeutics'average media sentiment score.

Company	Overall Sentiment
TScan Therapeutics	Neutral
Werewolf Therapeutics	Neutral

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TScan Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 466.04%. Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 1,001.65%. Given Werewolf Therapeutics' higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than TScan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

TScan Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

Werewolf Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. TScan Therapeutics' return on equity of -91.94% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

Summary

TScan Therapeutics beats Werewolf Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Werewolf Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HOWL vs. The Competition

Export

Metric	Werewolf Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.54M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.27	21.61	28.02	24.70
Price / Sales	8.80	340.19	540.37	99.46
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.67	8.66	10.96	6.46
Net Income	-$60.82M	$23.81M	$3.57B	$337.01M
7 Day Performance	5.39%	3.39%	2.12%	1.69%
1 Month Performance	-13.23%	10.81%	5.25%	3.81%
1 Year Performance	-68.51%	62.61%	33.29%	23.90%

Werewolf Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HOWL Werewolf Therapeutics	2.6366 of 5 stars	$0.34 flat	$3.75 +1,001.6%	-68.5%	$16.54M	$1.88M	N/A	40	Gap Up
SCLX Scilex	0.5728 of 5 stars	$7.80 flat	N/A	+30.2%	$66.22M	$30.25M	N/A	80
CYPH Cypherpunk Technologies	2.1952 of 5 stars	$0.61 -3.6%	N/A	+131.3%	$65.19M	N/A	N/A	40	News Coverage Analyst Forecast Gap Up
MNOV MediciNova	2.416 of 5 stars	$1.32 +0.8%	$8.33 +531.3%	+13.5%	$64.97M	$410K	N/A	10	Short Interest Decrease
ANVS Annovis Bio	2.4664 of 5 stars	$1.86 -0.3%	$13.50 +627.8%	-18.9%	$64.27M	N/A	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HOWL) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Werewolf Therapeutics (HOWL) Competitors

HOWL vs. SCLX, CYPH, MNOV, ANVS, and TCRX

How does Werewolf Therapeutics compare to Scilex?

Summary

How does Werewolf Therapeutics compare to Cypherpunk Technologies?

Summary

How does Werewolf Therapeutics compare to MediciNova?

Summary

How does Werewolf Therapeutics compare to Annovis Bio?

Summary

How does Werewolf Therapeutics compare to TScan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL vs. The Competition

Werewolf Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Werewolf Therapeutics (HOWL) Competitors

HOWL vs. SCLX, CYPH, MNOV, ANVS, and TCRX

How does Werewolf Therapeutics compare to Scilex?

Does the media prefer SCLX or HOWL?

Do analysts rate SCLX or HOWL?

Which has higher valuation & earnings, SCLX or HOWL?

Which has more risk & volatility, SCLX or HOWL?

Do insiders & institutionals believe in SCLX or HOWL?

Is SCLX or HOWL more profitable?

Summary

How does Werewolf Therapeutics compare to Cypherpunk Technologies?

Do analysts rate HOWL or CYPH?

Which has preferable valuation and earnings, HOWL or CYPH?

Do institutionals and insiders have more ownership in HOWL or CYPH?

Does the media prefer HOWL or CYPH?

Is HOWL or CYPH more profitable?

Which has more risk and volatility, HOWL or CYPH?

Summary

How does Werewolf Therapeutics compare to MediciNova?

Does the media refer more to MNOV or HOWL?

Do insiders and institutionals hold more shares of MNOV or HOWL?

Is MNOV or HOWL more profitable?

Which has more risk and volatility, MNOV or HOWL?

Which has higher earnings and valuation, MNOV or HOWL?

Do analysts recommend MNOV or HOWL?

Summary

How does Werewolf Therapeutics compare to Annovis Bio?

Which has preferable valuation & earnings, HOWL or ANVS?

Does the media prefer HOWL or ANVS?

Do insiders & institutionals hold more shares of HOWL or ANVS?

Which has more volatility & risk, HOWL or ANVS?

Is HOWL or ANVS more profitable?

Do analysts rate HOWL or ANVS?

Summary

How does Werewolf Therapeutics compare to TScan Therapeutics?

Which has stronger valuation & earnings, TCRX or HOWL?

Does the media refer more to TCRX or HOWL?

Do insiders and institutionals have more ownership in TCRX or HOWL?

Do analysts prefer TCRX or HOWL?

Which has more risk & volatility, TCRX or HOWL?

Is TCRX or HOWL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL vs. The Competition

Werewolf Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools